期刊
LEUKEMIA RESEARCH
卷 37, 期 3, 页码 259-265出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.leukres.2012.11.017
关键词
Health-related quality of life; Myelodysplastic syndrome; Anemia; clinical trial
We report health-related quality of life (HRQL) outcomes assessed using the Functional Assessment of Cancer Therapy-Anemia (FACT-An) among 167 RBC transfusion-dependent patients with IPSS Low-/Intermediate-1-risk del5q31 MDS treated with lenalidomide versus placebo in a randomized phase 3 clinical trial, MDS-004. Mean baseline to 12 week changes in FACT-An Total scores improved following treatment with lenalidomide 5 and 10 mg (+5.7 and +5.7, respectively) versus placebo (-2.8) (both p < 0.05). Clinically important changes in HRQL from baseline were observed at weeks 12, 24, 36, and 48 among RBC-TI >= 26 week responders in both treatment groups. Lenalidomide treatment may be effective in improving HRQL outcomes. (C) 2012 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据